• search hit 5 of 27
Back to Result List

Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases

Please always quote using this URN: urn:nbn:de:bvb:20-opus-135254
  • Background: Recently published results of quality of life (QoL) studies indicated different outcomes of palliative radiotherapy for brain metastases. This prospective multi-center QoL study of patients with brain metastases was designed to investigate which QoL domains improve or worsen after palliative radiotherapy and which might provide prognostic information. Methods: From 01/2007-01/2009, n=151 patients with previously untreated brain metastases were recruited at 14 centers in Germany and Austria. Most patients (82 %) receivedBackground: Recently published results of quality of life (QoL) studies indicated different outcomes of palliative radiotherapy for brain metastases. This prospective multi-center QoL study of patients with brain metastases was designed to investigate which QoL domains improve or worsen after palliative radiotherapy and which might provide prognostic information. Methods: From 01/2007-01/2009, n=151 patients with previously untreated brain metastases were recruited at 14 centers in Germany and Austria. Most patients (82 %) received whole-brain radiotherapy. QoL was measured with the EORTC-QLQ-C15-PAL and brain module BN20 before the start of radiotherapy and after 3 months. Results: At 3 months, 88/142 (62 %) survived. Nine patients were not able to be followed up. 62 patients (70.5 % of 3-month survivors) completed the second set of questionnaires. Three months after the start of radiotherapy QoL deteriorated significantly in the areas of global QoL, physical function, fatigue, nausea, pain, appetite loss, hair loss, drowsiness, motor dysfunction, communication deficit and weakness of legs. Although the use of corticosteroid at 3 months could be reduced compared to pre-treatment (63 % vs. 37 %), the score for headaches remained stable. Initial QoL at the start of treatment was better in those alive than in those deceased at 3 months, significantly for physical function, motor dysfunction and the symptom scales fatigue, pain, appetite loss and weakness of legs. In a multivariate model, lower Karnofsky performance score, higher age and higher pain ratings before radiotherapy were prognostic of 3-month survival. Conclusions: Moderate deterioration in several QoL domains was predominantly observed three months after start of palliative radiotherapy for brain metastases. Future studies will need to address the individual subjective benefit or burden from such treatment. Baseline QoL scores before palliative radiotherapy for brain metastases may contain prognostic information.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Diana Steinmann, Yvonne Paelecke-Habermann, Hans Geinitz, Raimund Aschoff, Anja Bayerl, Tobias Bölling, Elisabeth Bosch, Frank Bruns, Ute Eichenseder-Seiss, Johanna Gerstein, Nadine Gharbi, Juliane Hagg, Matthias Hipp, Irmgard Kleff, Axel Müller, Christof Schäfer, Ursula Schleicher, Susanne Sehlen, Marilena Theodorou, Hans-Joachim Wypior, Franz Zehentmayr, Birgitt van Oorschot, Dirk Vordermark
URN:urn:nbn:de:bvb:20-opus-135254
Document Type:Journal article
Faculties:Medizinische Fakultät / Klinik und Poliklinik für Strahlentherapie
Language:English
Parent Title (English):BMC Cancer
Year of Completion:2012
Volume:12
Issue:283
Source:BMC Cancer 2012, 12:283. doi:10.1186/1471-2407-12-283
DOI:https://doi.org/10.1186/1471-2407-12-283
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 616 Krankheiten
Tag:EORTC-BN20; EORTC-QLQ-C15-PAL; brain tumours; breast cancer; cancer patients; clinical trials; lung cancer; partitioning analysis RPA; prognostic index; radiation oncology; survival; symptoms; validation; whole-brain radiotherapy
Release Date:2018/03/23
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung